TOT BIOPHARM International Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

TOT BIOPHARM International heeft een totaal eigen vermogen van CN¥723.9M en een totale schuld van CN¥383.0M, wat de schuld-eigenvermogensverhouding op 52.9% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥1.5B en CN¥732.8M. De EBIT TOT BIOPHARM International is CN¥26.8M waardoor de rentedekking 9.2 is. Het heeft contanten en kortetermijnbeleggingen van CN¥348.4M.

Belangrijke informatie

52.9%

Verhouding schuld/eigen vermogen

CN¥383.01m

Schuld

Rente dekkingsratio	9.2x
Contant	CN¥348.35m
Aandelen	CN¥723.89m
Totaal verplichtingen	CN¥732.77m
Totaal activa	CN¥1.46b

Recente financiële gezondheidsupdates

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Jul 27

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Feb 03

Recent updates

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07

The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

May 21

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Mar 18

There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Dec 28

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

Nov 23

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

May 18

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Jul 27

An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Mar 26

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Feb 03

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥720.3M ) 1875 } overtreffen de korte termijn passiva ( CN¥372.0M ).

Langlopende schulden: De kortetermijnactiva 1875 ( CN¥720.3M ) overtreffen de langetermijnschulden ( CN¥360.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 4.8% ) 1875 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1875 is de afgelopen 5 jaar gedaald van 126.3% naar 52.9%.

Schuldendekking: De schuld van 1875 wordt niet goed gedekt door de operationele kasstroom ( 5.7% ).

Rentedekking: De rentebetalingen op de schuld van 1875 worden goed gedekt door EBIT ( 9.2 x dekking).

TOT BIOPHARM International Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Recent updates

First half 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.021 loss in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.021 loss in 1H 2023)

TOT BIOPHARM International Company Limited to Report Q2, 2024 Results on Aug 13, 2024

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

TOT BIOPHARM International Company Limited, Annual General Meeting, Jun 14, 2024

The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.078 loss in FY 2022)

TOT BIOPHARM International Company Limited to Report Fiscal Year 2023 Results on Mar 15, 2024

There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Less than half of directors are independent

First half 2023 earnings released: CN¥0.021 loss per share (vs CN¥0.027 loss in 1H 2022)

TOT BIOPHARM International Company Limited Announces Directorate and Committee Changes

TOT BIOPHARM International Company Limited to Report First Half, 2023 Results on Aug 11, 2023

TOT BIOPHARM International Company Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: CN¥0.08 loss per share (vs CN¥0.46 loss in FY 2021)

Executive Vice Chairman of the Board recently sold HK$4.1m worth of stock

Less than half of directors are independent

First half 2022 earnings released

TOT BIOPHARM International Company Limited to Report Q2, 2022 Results on Aug 12, 2022

TOT BIOPHARM International Company Limited has completed a Follow-on Equity Offering in the amount of HKD 472.5 million.

TOT BIOPHARM International Company Limited, Annual General Meeting, Jun 28, 2022

TOT BIOPHARM International Company Limited announced that it expects to receive HKD 110 million in funding from Center Laboratories, Inc.

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

Less than half of directors are independent

TOT BIOPHARM International Company Limited Announces Change of Joint Company Secretary and Finance Personnel

TOT BIOPHARM International Company Limited Announces NMPA Granted Marketing Approval for Pusintin in China

First half 2021 earnings released: CN¥0.20 loss per share (vs CN¥0.23 loss in 1H 2020)

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Tot Biopharm International Company Limited Announces Drug Registration Approval for Temozolomide Capsule (TOZ309) Obtained from the National Medical Products Administration

Full year 2020 earnings released: CN¥0.51 loss per share (vs CN¥0.89 loss in FY 2019)

An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Full year 2020 earnings released

TOT BIOPHARM International Company Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: HK$4.02

TOT BIOPHARM International Company Limited Provides Update to its Phase III Clinical Trial Application of TAB014 Authorized by United States Food and Drug Administration

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

TOT BIOPHARM International Company Limited Announces Appointment of Liu, Jun as the Chief Executive Officer

First half earnings released

New 90-day low - HK$3.94

Earnings released

TOT BIOPHARM International Company Limited to Report First Half, 2020 Results on Aug 13, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven